Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12755493 | 0.85 | MMP9 (0.41) | MMP9MAPTKDM4EALDH1A1HSD17B10 | |
| SCHEMBL28249865 | 0.73 | POLB (0.49) | MMP9MAPTKDM4EALDH1A1HSD17B10 | |
| SCHEMBL27348939 | 0.73 | MAPT (0.39) | MMP9MAPTKDM4EALDH1A1HSD17B10 | |
| SCHEMBL8345923 | 0.72 | MAPT (0.47) | MMP9MAPTKDM4EALDH1A1HSD17B10 | |
| SCHEMBL27545804 | 0.72 | MAPT (0.38) | MMP9MAPTKDM4EALDH1A1HSD17B10 | |
| SCHEMBL4546569 | 0.71 | KDM4E (0.50) | MMP9MAPTKDM4EALDH1A1HSD17B10 | |
| SCHEMBL890208 | 0.71 | ALOX5 (0.54) | MAPTALDH1A1LMNA | |
| SCHEMBL890241 | 0.70 | HIF1A (0.42) | MAPTKDM4ETP53SMN1; SMN2LMNA | |
| SCHEMBL8119056 | 0.70 | MMP9 (0.43) | MMP9MAPTKDM4EALDH1A1HSD17B10 | |
| SCHEMBL7507198 | 0.70 | PRNP (0.41) | MAPTKDM4EALDH1A1OPRM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110070196-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070196-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | MMP9 3146/4885MAPT 4286/4885KDM4E 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.